← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleNovartis PharmaceuticalsPhase 2

CDK4/6 inhibitor+AI or fulvestrant (CDK4/6 inhibitor+AI or fulvestrant)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 19.3%임상시험 11상태 RECRUITING
AntibodystaleShi MingPhase 2

Candonilimab (Candonilimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 11상태 DISCONTINUED
ADCBiologicstaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 56.5%임상시험 11상태 RECRUITING
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 3

JSKN003 (JSKN003)

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 11상태 RECRUITING
CGTBiologicstaleKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 11상태 RECRUITING
AntibodystaleLepu Medical Technology (Beijin…Phase 2

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Oral and Oropharyngeal

#LocallyAdvancedOralandOropharyng#Antibody#Phase2#항체#면역항체+2
임상시험 11상태 RECRUITING
ADCBiologicstaleRochePhase 1

ado-trastuzumab emtansine (Kadcyla, T-DM1, PD-0332991 and T-DM1)

Advanced Breast Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 11상태 ACTIVE
ADCBiologicstalePfizerPhase 2

PF-08634404 (PF-08634404)

Urothelial Cancer; Advanced/Metastatic Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 11상태 RECRUITING
AntibodystaleAmgenPhase 2

Panitumumab-IRDye800 (Panitumumab-IRDye800)

Pancreatic Adenocarcinoma · Malignant Brain Neoplasm

#MalignantBrainNeoplasm#Antibody#Phase2#항체#면역항체+3
임상시험 11상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

Ovarian Cancer; HER2 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 11상태 RECRUITING
AntibodystaleJanssenPhase 1

Topical infliximab (Topical infliximab)

Sterile Corneal Melt · Glaucoma Following Surgery

#GlaucomaFollowingSurgery#Antibody#Phase1#항체#면역항체+3
임상시험 11상태 ACTIVE
AntibodystaleNeovii BiotechPhase 2

Transplant Conditioning with Mobilization and Alemtuzumab (Transplant Conditioning with Mobilization and Alemtuzumab)

Severe Combined Immunodeficiency · Severe Combined Immunodeficiency

#SevereCombinedImmunodeficiency#Antibody#Phase2#항체#면역항체+2
임상시험 11상태 DISCONTINUED
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 11상태 ACTIVE
ADCBiologicstaleHoffmann-La RochePhase 2

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 RECRUITING
CGTBiologicstaleNational Heart, Lung, and Blood…vedotinPhase 1

AVL (AAV8hAAT, AAV8hAAT(AVL))

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 10상태 RECRUITING
ADCBiologicstaleAstellas Pharma IncPhase 1

AGS-22M6E (AGS-22M6E)

Tumors; Medical Oncology · Tumors

#Tumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 10상태 ACTIVE
CGTBiologicstaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 10상태 ACTIVE
CGTBiologicstaleTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 20%임상시험 10상태 RECRUITING
AntibodystaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+3
임상시험 10상태 RECRUITING
CGTBiologicstaleShenzhen Celconta Life Science …Phase 1

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 10상태 RECRUITING

43 / 177 페이지

← 이전다음 →